Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial

Christian Antoni ¹, Gerald G Krueger ², Kurt de Vlam ³, Charles Birbara ⁴, Anna Beutler ⁵, Cynthia Guzzo ⁵, Bei Zhou ⁵, Lisa T Dooley ⁵ and Arthur Kavanaugh ^6*

¹ Friedrich Alexander University of Erlangen-Nurnberg, Germany
² University of Utah Health Sciences Center, United States
³ University Hospital Leuven, Belguim
⁴ University of Massachusetts School of Medicine, United States
⁵ Centocor, Inc., United States
⁶ University of California San Diego, United States

^* To whom correspondence should be addressed. E-mail: akavanaugh{at}ucsd.edu.

Accepted 16 January 2005

Abstract

Objectives: This phase III, double-blind trial further evaluated the efficacy of infliximab in active psoriatic arthritis (PsA), as observed in the smaller IMPACT trial.

Methods: Two hundred patients with active PsA unresponsive to prior therapy were randomized to infusions of infliximab 5 mg/kg or placebo at weeks 0, 2, 6, 14, and 22. Patients with inadequate response entered early escape at week 16. The primary measure of clinical response was ACR 20. Other measures included Psoriatic Arthritis Response Criteria (PsARC), Psoriasis Area and Severity Index (PASI), and dactylitis and enthesopathy assessments.

Results: At week 14, 58.0% of infliximab patients and 11.0% of placebo patients achieved an ACR 20 response and 77% of infliximab patients and 27.0% of placebo patients achieved PsARC (both p<0.001). Among the 85% of patients with at least 3% body surface area psoriasis involvement at baseline, 63.9% of infliximab patients had at least 75% improvement in PASI compared with 2.3% of placebo patients at week 14 (p<0.001). These therapeutic effects were maintained through the last evaluation (week 24). Fewer infliximab patients than placebo patients had dactylitis at week 14 (18.2% versus 30.0%; p=0.025) and week 24 (11.8% versus 34.0%; p<0.001). Fewer infliximab patients (22.2%) than placebo patients (33.7%) had active enthesopathy at week 14 (p=0.016); corresponding figures at week 24 were 20.4% and 37.2% (p=0.002). Infliximab was generally well tolerated, with a similar incidence of adverse events in each group.

Conclusions: Infliximab 5 mg/kg through 24 weeks significantly improved active PsA, including dactylitis and enthesopathy, and associated psoriasis.

Keywords: TNF-alpha, dactylitis, enthesopathy, infliximab, psoriatic arthritis

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• BARRA, L., POPE, J. E., PAYNE, M. (2009). Real-World Anti-Tumor Necrosis Factor Treatment in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis: Cost-Effectiveness Based on Number Needed to Treat to Improve Health Assessment Questionnaire. The Journal of Rheumatology 36: 1421-1428 [Abstract] [Full Text]  
• Eroschenko, K., Cleveland, K. W., Gunter, K. (2009). Psoriatic Arthritis: A Review. Journal of Pharmacy Practice 22: 86-103 [Abstract]  
• Furst, D E, Keystone, E C, Kirkham, B, Fleischmann, R, Mease, P, Breedveld, F C, Smolen, J S, Kalden, J R, Burmester, G R, Braun, J, Emery, P, Winthrop, K, Bresnihan, B, De Benedetti, F, Dorner, T, Gibofsky, A, Schiff, M H, Sieper, J, Singer, N, Van Riel, P L C M, Weinblatt, M E, Weisman, M H (2008). Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis 67: iii2-iii25 [Full Text]  
• Ahern, M J, Campbell, D G, Weedon, H, Papangelis, V, Smith, M D (2008). Effect of intra-articular infliximab on synovial membrane pathology in a patient with a seronegative spondyloarthropathy. Ann Rheum Dis 67: 1339-1342 [Abstract] [Full Text]  
• Yazici, Y., Adler, N. M., Yazici, H. (2008). Most tumour necrosis factor inhibitor trials in rheumatology are undeservedly called 'efficacy and safety' trials: a survey of power considerations. Rheumatology (Oxford) 47: 1054-1057 [Abstract] [Full Text]  
• Ravindran, V, Scott, D L, Choy, E H (2008). A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis. Ann Rheum Dis 67: 855-859 [Abstract] [Full Text]  
• Coates, L C, Cawkwell, L S, Ng, N W F, Bennett, A N, Bryer, D J, Fraser, A D, Emery, P, Marzo-Ortega, H (2008). Sustained response to long-term biologics and switching in psoriatic arthritis: results from real life experience. Ann Rheum Dis 67: 717-719 [Abstract] [Full Text]  
• Tsiodras, S., Samonis, G., Boumpas, D. T., Kontoyiannis, D. P. (2008). Fungal Infections Complicating Tumor Necrosis Factor {alpha} Blockade Therapy. Mayo Clin Proc. 83: 181-194 [Abstract] [Full Text]  
• Taylor, W. J., Helliwell, P. S. (2007). Psoriatic arthritis is a joint-damaging disease a call for action!. Rheumatology (Oxford) 46: 1747-1748 [Full Text]  
• Furst, D E, Breedveld, F C, Kalden, J R, Smolen, J S, Burmester, G R, Sieper, J, Emery, P, Keystone, E C, Schiff, M H, Mease, P, van Riel, P L C M, Fleischmann, R, Weisman, M H, Weinblatt, M E (2007). Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis 66: iii2-iii22 [Full Text]  
• Heiberg, M S, Kaufmann, C, Rodevand, E, Mikkelsen, K, Koldingsnes, W, Mowinckel, P, Kvien, T K (2007). The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study. Ann Rheum Dis 66: 1038-1042 [Abstract] [Full Text]  
• Kavanaugh, A, Krueger, G G, Beutler, A, Guzzo, C, Zhou, B, Dooley, L T, Mease, P J, Gladman, D D, de Vlam, K, Geusens, P P, Birbara, C, Halter, D G, Antoni, C, for the IMPACT 2 Study Group, (2007). Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis 66: 498-505 [Abstract] [Full Text]  
• Gratacos, J, Casado, E, Real, J, Torre-Alonso, J C (2007). Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexate. Ann Rheum Dis 66: 493-497 [Abstract] [Full Text]  
• Voulgari, P. V, Venetsanopoulou, A. I, Epagelis, E. K, Alamanos, Y., Takalou, I., Drosos, A. A (2007). Infliximab in refractory psoriatic arthritis with severe psoriasis: a 2-year experience. Ann Rheum Dis 66: 270-271 [Full Text]  
• Yazici, Y, Yazici, H (2007). A survey of inclusion of the time element when reporting adverse effects in randomised controlled trials of cyclo-oxygenase-2 and tumour necrosis factor {alpha} inhibitors. Ann Rheum Dis 66: 124-127 [Abstract] [Full Text]  
• Kay, L. J., Griffiths, I. D., for the BSR Biologics Register Management committe, (2006). UK consultant rheumatologists' access to biological agents and views on the BSR Biologics Register. Rheumatology (Oxford) 45: 1376-1379 [Abstract] [Full Text]  
• Bansback, N. J., Ara, R., Barkham, N., Brennan, A., Fraser, A. D., Conway, P., Reynolds, A., Emery, P. (2006). Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis. Rheumatology (Oxford) 45: 1029-1038 [Abstract] [Full Text]  
• Kavanaugh, A. (2006). Pharmacoeconomic considerations in the treatment of psoriatic arthritis. Rheumatology (Oxford) 45: 790-791 [Full Text]  
• Kavanaugh, A, Antoni, C, Krueger, G G, Yan, S, Bala, M, Dooley, L T, Beutler, A, Guzzo, C, Gladman, D (2006). Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis. Ann Rheum Dis 65: 471-477 [Abstract] [Full Text]  
• Braun, J, Davis, J, Dougados, M, Sieper, J, van der Linden, S, van der Heijde, D, for the ASAS Working Group, (2006). First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 65: 316-320 [Abstract] [Full Text]  
• (2006). New drugs for peripheral joint psoriatic arthritis. DTB 44: 1-5 [Abstract] [Full Text]  
• Furst, D E, Breedveld, F C, Kalden, J R, Smolen, J S, Burmester, G R, Bijlsma, J W J, Dougados, M, Emery, P, Keystone, E C, Klareskog, L, Mease, P J (2005). Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis 64: iv2-iv14 [Full Text]